Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update

CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimi...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Pharmacol Ther
Main Authors: Hicks, J. Kevin, Sangkuhl, Katrin, Swen, Jesse J., Ellingrod, Vicki L., Müller, Daniel J., Shimoda, Kazutaka, Bishop, Jeffrey R., Kharasch, Evan D., Skaar, Todd C., Gaedigk, Andrea, Dunnenberger, Henry M., Klein, Teri E., Caudle, Kelly E., Stingl, Julia C.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478479/
https://ncbi.nlm.nih.gov/pubmed/27997040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.597
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares